Infection with Scedosporium species is associated with a significant morbidity and mortality and is becoming increasingly common, especially in immunocompromised patients. We describe the presentation and successful management of an immunocompromised patient with Scedosporium apiospermum infection of the upper urinary tract system, a rare disease manifestation. The current literature on urinary tract scedosporiosis is further reviewed with emphasis on treatment options and limitations of current antifungal therapy.
| INTRODUCTION
Scedosporium species is a ubiquitous, saprophytic, filamentous mold found in soil, sewage, polluted water, and compost. 1 It is an increasingly prevalent and devastating cause of infection in immunocompromised patients. 2 In the transplant population, Scedosporium species accounts for 25% of non-Aspergillus mold infections, the third most common after Mucorales and Fusarium species. 3 Scedosporium infections are caused mainly by Scedosporium apiospermum and Lomentospora prolificans (formerly known as Scedosporium prolificans). Disseminated infection is the most common form of disease, often involving the central nervous system or pulmonary or integumentary systems. 2, 4 Invasion of the urinary system has rarely been described and is usually a late manifestation of otherwise disseminated disease.
Infection with Scedosporium species often requires prolonged antifungal therapy as well as surgical intervention, but outcomes remain poor, with mortality rates as high as 71% in disseminated cases. 4 Treatment is challenging in part owing to the organism's resistance profile, difficulties in achieving adequate antifungal drug levels in infected tissues, and toxicities associated with antifungal therapies.
We describe below an unusual case of S. apiospermum infection in an immunocompromised patient with primary manifestation in the urinary system, treated successfully using a combination of antifungal and surgical therapy. We review the available literature on Scedosporium infections of the urinary system and discuss the clinically relevant question of antifungal penetration into renal parenchyma and urine.
| CASE DESCRIPTION
A previously healthy 27-year-old male was diagnosed in August 2015 with precursor B-cell acute lymphoid leukemia and underwent induction chemotherapy with CALBG protocol 10403. 
| DISCUSSION
In immunocompromised hosts, angioinvasion with Scedosporium species is more frequent and can result in fungemia with hematogenous dissemination. While dissemination likely occurred in our patient, the only symptomatic manifestation and confirmed area of involvement were in the urinary system.
| A review of the literature on urinary scedosporiosis
Scedosporiosis of the urinary tract has been rarely described. Review of cases' search criteria were "scedosporium" and "genitourinary" or "urine" or "urinary" or "kidney." Among the nine cases found in the literature, all involved disseminated Scedosporium infection in immunocompromised hosts (Table 1) . 1, [7] [8] [9] [10] [11] [12] [13] In seven of these cases, urinary involvement was asymptomatic, and in five cases, urinary involvement was only discovered postmortem. Five patients grew Scedosporium species in blood cultures. Six cases involved L. prolificans, and the remaining three involved S. apiospermum. All but one patient had a fatal outcome; six died within a month of presentation, with five deaths occurring prior to the initiation of appropriate antifungal therapy.
Only two cases had symptomatic involvement of the urinary system by Scedosporium species, manifested as ureteral obstruction. The first was a 63-year-old male who underwent bilateral lung transplantation for interstitial pneumonitis. 12 The therapy showed overall successful therapy in 57%, with success rate varying widely by sites of infection; central nervous system infections and disseminated infections had a 43% and 48% response rate, respectively, whereas skin and subcutaneous infections had a 91% response rate. 15 Combination therapy with VRC plus terbinafine or micafungin for synergy has also been used based on in vitro data suggesting 20-60-fold decrease in MIC, 14, 16 and at least a few successful case reports. 17, 18 Treatment of fungal infections of the urinary tract presents additional challenges given variable penetration of antifungals into urine and kidney tissue. Echinocandins readily penetrate and accumulate in renal tissue, reaching levels multiple times that of plasma. However, <2% is excreted into urine and has questionable efficacy for treatment of fungal or candidal cystitis. 19, 20 Of the azoles, only fluconazole reaches therapeutic levels in the urine and kidney. It penetrates renal tissue with levels up to 4× serum plasma levels and with ~80% excreted unchanged in the urine. VRC is also excreted in the urine; however, unlike fluconazole, VRC is excreted mostly as inactive metabolites and thus unlikely to be effective for urinary infections. Kidney tissue concentration of VRC appears to be adequate, with detectable levels in postmortem human kidney tissue and good efficacy for treating renal candidal infection in an animal model. [20] [21] [22] The pharmacokinetics of itraconazole and posaconazole regarding the urinary system are similar to VRC, with good renal parenchymal levels but minimal urinary excretion of the active drug.
20,21
Also like VRC, terbinafine is mostly excreted in the urine as an inactive metabolite, possibly rendering it ineffective for urinary tract infection. Although a study in rats demonstrated detectable levels of terbinafine in kidney tissue, the majority of drug accumulation was in adipose and skin, with kidney levels falling below the level of detection 4 hours after administration.
23
AmB deoxycholate is not used for the treatment of Scedosporium species owing to a lack of efficacy. However, it also readily accumulates in the kidneys and has good urinary excretion. The lipid formulations of AmB are preferred because of their decreased renal toxicity as compared to deoxycholate, but have significantly lower levels of concentration in the kidney and urine, and failures in treating candiduria have been reported. 20, 21 Flucytosine is excreted almost completely unchanged in the urine and able to reach very high concentrations in the urine and high levels in renal parenchyma. 21 
| CONCLUSION
We have described a unique case of primary urinary scedosporiosis in an immunocompromised host successfully managed using combination antifungal therapy and surgical intervention. We chose a combination of VRC (and subsequently posaconzole) with micafungin and terbinafine for synergy, but it remains unclear which of these antifungals or their combinations were most effective. Surgical intervention has been previously shown to improve survival in patients with disseminated Scedosporium infections. 4 Given the patient's impending immunosuppression and the high morbidity and mortality associated with Scedosporium infections, we opted for an aggressive approach with good outcomes. At last follow-up in April 2017, 16 months post HSCT, the patient had no symptoms of infection relapse and was off all antifungal therapy.
As the number of transplant patients continues to grow and the threat of morbidity and mortality from fungal infections increases, it is important to recognize the ability of Scedosporium species to cause invasive disease including in the urinary system, the therapeutic options available, and the limitations of antifungal pharmacokinetics. 
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